TrumpRx Prescription Discount Website Shows Limited Impact Two Months After Launch

The TrumpRx website launched in early February 2026 with the aim to offer lower-priced drugs to those without insurance or those who would like to pay in cash, but the results are more complicated. The website, which acts as a central hub for prescription drug coupons, offers discounts for 43 brand-name prescription drugs including therapies for obesity, diabetes, and fertility, but experts say its usefulness is limited for most patients.

TrumpRx is a website hosted by the government where Americans can go to find brand-name prescription drugs at a discounted price. The coupons can be taken to specific pharmacies to get the discounted prices on existing prescriptions. However, there are few drugs listed on TrumpRx compared with the number of drugs available in the US, making the website's usefulness limited for some patients.

"For a lot of people who want to go to the website and see if their drug is covered, they might have that same experience where they try all the drugs that are in their medicine cabinet and nothing shows up," said one health policy expert. The website has 43 prescription drugs available, which may be found elsewhere.

"There are some drugs like GLP-1 medications for weight loss or hormonal treatments used in IVF that are often not covered by insurance, and in those cases having options to purchase these drugs at discounted cash prices can be useful," said a physician. "For most Americans, this won't be a great option because most people use insurance to pay for their prescription drugs and their out-of-pocket costs may be only a fraction of the full cost."

The launch of TrumpRx.gov operationalized an approach as a limited MFN-linked discount channel for cash-pay and uninsured patients, linking tariff exposure to pricing program eligibility. The Trump administration pursued Most Favored Nation (MFN)-style pricing commitments that linked tariff relief to price cuts for specific channels such as Medicaid and cash-pay programs.

Deals with pharmaceutical companies may have played a role in TrumpRx, though the details remain unclear. "We don't know all the details of these agreements, and perhaps more importantly, we don't know if these agreements can be enforced," said one expert. "Thus, it's hard to know if the drugs listed on TrumpRx are directly linked to these agreements or not."

Both sides have promised that the agreements include lowering prices for drugs overall, but how these reductions will be implemented has not been revealed. The voluntary nature of the agreements means that, at any point, the drug companies could potentially walk away from them.

TrumpRx shares some similarities with other websites that aim to provide coupons for prescription drugs, including GoodRx and Mark Cuban's Cost Plus Drugs. The latter two websites provide coupons for both branded and generic drugs, whereas TrumpRx provides brand-name drugs exclusively. Experts have found that 18 of the brand-name drugs that are available through TrumpRx are cheaper to buy through GoodRx or Cost Plus Drugs coupons, making it confusing for patients who are looking for the lowest prices when seeking to pay cash for their prescription drugs.

"TrumpRx is on the other side of that, where you might actually go and search for a drug and think you're getting a good deal...but it doesn't tell you if there's a generic option for that product," explained an expert. This could make for a frustrating experience for patients should they go through TrumpRx thinking that they're getting the best deal but ultimately pay more than they would find on other websites.

Because most of the drugs on TrumpRx are branded, they are often too expensive to pay for in cash for any long period of time, including cancer drugs. The policy developments in February 2026 expanded the administration's leverage beyond tariffs and manufacturing commitments, with PBM reforms under the Consolidated Appropriations Act 2026 increasing rebate transparency and pricing accountability across the distribution channel, further tightening the operating environment for branded drug pricing.